NRX Pharmaceuticals, Inc.
NRXP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001719406
No open-market purchases or sales by NRX Pharmaceuticals, Inc. insiders were filed in the last 90 days; 47 institutions reported holding it in 13F filings for Q2 2026, worth $47.6M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding NRX Pharmaceuticals, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 24 | 28 | +4 |
| Shares | 3.96M | 5.24M | +1.28M (+32.3%) |
| Value | $13.0M | $14.2M | +$1.13M (+8.6%) |
New holders (7)
Institutions that held NRX Pharmaceuticals, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Commonwealth Equity Services, LLC | 366,631 | $993.6K | 0.00% |
| Bleakley Financial Group, LLC | 117,204 | $317.6K | 0.01% |
| Global Retirement Partners, LLC | 39,300 | $106.5K | 0.00% |
| Point72 Asset Management, L.P. | 15,979 | $43.3K | 0.00% |
| Sjbenen Advisory, LLC | 15,000 | $40.6K | 0.04% |
| Royal Bank of Canada | 2,000 | $5.00K | 0.00% |
| Steward Partners Investment Advisory, LLC | 1 | $3 | 0.00% |
Sold out (3)
Institutions that held NRX Pharmaceuticals, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Marshall Wace, LLP | 189,136 | $624.1K |
| Renaissance Technologies LLC | 128,175 | $423.0K |
| Carolina Wealth Advisors, LLC | 50 | $165 |